Mint Tower Capital Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Mint Tower Capital Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-75,000	Closed	-$10K	–	171
2024 Q4	$10K	Hold	75,000	–	–	﹤0.01%	114
2024 Q3	$8K	Hold	75,000	–	–	﹤0.01%	114
2024 Q2	$8K	Hold	75,000	–	–	﹤0.01%	103
2024 Q1	$11K	Hold	75,000	–	–	﹤0.01%	146
2023 Q4	$11K	Hold	75,000	–	–	﹤0.01%	140
2023 Q3	$17K	Hold	75,000	–	–	﹤0.01%	211
2023 Q2	$14K	Hold	75,000	–	–	﹤0.01%	197
2023 Q1	$14K	Buy	+75,000	New	+$11.7K	﹤0.01%	217

Mint Tower Capital Management's BLACR Position: Q1 2025 in Review

Mint Tower Capital Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 75,000 shares — an estimated $10K sold.

Mint Tower Capital Management first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $17K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Mint Tower Capital Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Mint Tower Capital Management sold 75,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $10K.
Mint Tower Capital Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
Mint Tower Capital Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $17K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Mint Tower Capital Management's 13F filing for Q1 2025, filed 15 May 2025.